Abcam, ab228975, Anti-FCGRT/FCRN antibody [EPR22627-25]

Size: 100µL / 1mL
Anti-FCGRT/FCRN antibody [EPR22627-25] (ab228975) is a rabbit monoclonal antibody detecting FCGRT/FCRN in Western Blot, Flow Cytometry, IP, IHC-P . Suitable for Human . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22627-25,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WB, IP, Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-FCGRT/FCRN antibody [EPR22627-25] (ab228975) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunohistochemistry (IHC-P) in Human samples.
What is the molecular weight of FCGRT/FCRN?
Anti-FCGRT/FCRN [EPR22627-25] (ab228975) specifically detects a band for FCGRT/FCRN (UniProt: P55899) at a molecular weight of 40kDa.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Specificity confirmed
The specificity of Anti-FCGRT/FCRN antibody [EPR22627-25] (ab228975) has been confirmed by Western blot testing in FCGRT Knockout HEK293T cell line,
ab265075
Other related products
We have a range of other formats of antibody clone [EPR22627-25] also available for your convenience: ab228975, Carrier free -
ab256121
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein FCGRT also known as FCRN or FcRn has a significant role in the immune system by binding to the Fc region of immunoglobulin G (IgG). This binding prolongs the half-life of IgG by preventing its lysosomal degradation. The molecular mass of the FCGRT protein is roughly 52 kDa. It is prominently expressed in epithelial and endothelial cells across several tissues including the placenta and liver ensuring IgG stability in circulation.
Biological function summary
FCGRT/FCRN is involved in the transportation and recycling of IgG antibodies. It forms a complex with beta-2 microglobulin that contributes to its function. This complex allows IgG antibodies to traverse cellular barriers such as epithelial cells without being digested. This protein is important in maintaining humoral immunity by regulating IgG levels in the bloodstream and similar processes can be observed in mouse FCRN and cynomolgus monkey milk indicating a conserved mechanism across species.
Pathways
FCGRT/FCRN plays a part in the neonatal Fc receptor pathway. This pathway influences IgG homeostasis and impacts antigen presentation to T cells. By doing so it affects immune surveillance and immune tolerance mechanisms. The pathway involves interactions with related proteins such as albumin which also binds to FCRN for extending its half-life in serum.
Disruptions in FCGRT/FCRN functionality relate to autoimmune conditions and inflammatory diseases. Conditions such as lupus and myasthenia gravis show altered IgG recycling or transportation implicating FCRN in their pathology. Accordingly researchers have explored FCRN inhibitors as potential therapeutic interventions. These inhibitors aim to modulate the interaction between FCRN and IgG therefore impacting the disease progression linked to these disorders.